By Kamal Choudhury March 26 (Reuters) - Wave Life Sciences shares plunged 58% on Thursday after a higher dose of its experimental obesity drug failed to show a clear improvement at reducing a ...
Hello, and welcome to Wave Life Sciences Positive Interim Phase I Clinical Data from INLIGHT Trial of WVE-007 for Obesity Call. [Operator Instructions] Also, as a reminder, this conference is being ...
Wave Life Sciences (WVE) stock plunges as the company interim data from an early-stage trial for WVE-007, its RNA-based ...
Wave Life Sciences (NASDAQ:WVE) shares are trading near historic lows after two Wall Street firms cut their price targets ...
SELLAS Life Sciences Group Inc. (NASDAQ:SLS) is one of the popular penny stocks on Robinhood to buy. On March 17, SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) announced that it will present ...
Barchart on MSN
Wave Life Sciences crashes deep into oversold territory as obesity drug data disappoints. Should you buy the dip?
Wave Life Sciences (WVE) shares crashed more than 50% on Mardh 26 after the company’s interim Phase 1 data for its obesity ...
On March 26, 2026, traders mulled Wave's weak high-dose obesity results against the company's large market opportunity.
Loomis Sayles, an investment management company, released its fourth-quarter 2025 investor letter for “Small Cap Growth Fund” ...
Read about the new Biocom Octane partnership. Discover how this collaboration expands capital and accelerator access for ...
Wave Life Sciences Ltd. (NASDAQ:WVE) shares fell 30% Thursday following the company’s announcement of interim Phase 1 data ...
W hile challenges persist in the short term, there are signs pointing toward long-term growth for life sciences, according to JLL’s 2024 Life Sciences Real Estate Perspective and Cluster Analysis. The ...
Dr. Mark Turco "will step down" from his role with the Hub Wednesday, March 11, to lead a medical device company.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results